A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

The oral factor XIa inhibitor milvexian across a range of doses is associated with a lower risk of venous thromboembolism (VTE) after knee arthroplasty than subcutaneous enoxaparin (Lovenox) without ...

Factor XIa inhibitor milvexian did not provide meaningful secondary prevention over dual antiplatelet therapy for stroke survivors, the phase II trial AXIOMATIC-SSP found. In patients with recent ...

Tumor necrosis factor (TNF) inhibitors are associated with a reduced risk for recurrent cardiovascular events in patients with radiographic axial spondyloarthritis (axSpA) and a history of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In patients with AF requiring anticoagulation, the ...

The coagulation cascade is a finely balanced system essential for maintaining haemostasis, yet its disruption can lead to either a propensity for bleeding or an increased risk of clot formation.

Add a second biologic or JAK1 inhibitor to biologic monotherapyAvoid adding an IL-1 inhibitor, which could raise infection risk ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...

"It should be enormously satisfying to the cardiovascular field, patients and providers that Factor XI inhibitors live up to their promise of superior safety," said Christian Ruff, MD, MPH, director ...